Toxicité de l'alpha-synucléine dans le modèle de souris GFAP.HMOX1 de la maladie de Parkinson


Marisa Cressatti

Institut Lady Davis de recherches médicales de l'Hôpital général juif


Domaine : vieillissement

Programme Formation de doctorat

Concours 2018-2019

Partenaire :

Parkinson Canada

Parkinson disease (PD) is the second most common neurodegenerative disorder, affecting 2% of the population over 65 years of age. Although several drugs are available to alleviate some of the symptoms of PD (such as tremor or stiffness), we sorely lack medications which slow the destruction of nerve cells in the affected brain regions. Two abnormalities observed in the PD brain which are thought to contribute to nerve cell damage in this disease are 1) the excessive accumulation of iron, and 2) injury to mitochondria, the cells' power generators. The Schipper laboratory has collected evidence that both of these abnormalities may be caused by an enzyme called heme oxygenase-1 (HO-1), which is overactive in the brains of PD patients.

We recently created a mouse model that mimics the increased brain HO-1 seen in individuals with PD. In the current proposal, we will document the deleterious effects of this excessive HO-1 and how it relates to other hallmarks of the PD brain, including the formation of clusters of aggregated proteins called Lewy bodies. If successful, this study may identify HO-1 as a potential therapeutic target for the prevention of brain cell loss in PD and provide fresh hope to sufferers of this debilitating condition.